MarketCap
Alterity Therapeutics Limited ATHE
€ 2.18
7.02%
Facebook
X
Telegram
Alterity Therapeutics Limited Betriebsaufwand | ATHE
Betriebsaufwand Jährlich Alterity Therapeutics Limited
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | - | - | - | - | 16.7 M | 28.1 M | 16.4 M | 7.83 M | 6.44 M |
Jährliche Entwicklung
Kennzahlen zur Anzeige auswählen
Alle Zahlen in AUD-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 28.1 M | 6.44 M | 15.1 M |
Betriebsaufwand anderer Aktien in der Pharmaeinzelhändler
| Name | Betriebsaufwand | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
 |
United Therapeutics Corporation
UTHR
|
1.31 B | $ 562.14 | -0.63 % | $ 24.9 B |  USA |
 |
Vericel Corporation
VCEL
|
195 M | $ 54.56 | 5.36 % | $ 2.75 B | USA |
 |
Veracyte
VCYT
|
305 M | $ 24.1 | 0.42 % | $ 1.89 B | USA |
 |
Applied Molecular Transport
AMTI
|
127 M | - | - | $ 10.1 M | USA |
 |
Fulcrum Therapeutics
FULC
|
84.8 M | $ 3.72 | 0.95 % | $ 236 M | USA |
 |
Molecular Templates
MTEM
|
67.8 M | - | -23.43 % | $ 495 K | USA |
 |
Vanda Pharmaceuticals
VNDA
|
354 M | $ 3.82 | 6.27 % | $ 225 M | USA |
 |
Verrica Pharmaceuticals
VRCA
|
47.8 M | $ 3.22 | 4.21 % | $ 34.3 M | USA |
 |
Viridian Therapeutics
VRDN
|
434 M | $ 28.47 | -0.28 % | $ 2.9 B | USA |
 |
BioXcel Therapeutics
BTAI
|
107 M | $ 0.07 | 9.81 % | $ 855 K | USA |
 |
VistaGen Therapeutics
VTGN
|
73.4 M | $ 0.17 | 3.45 % | $ 6.47 M | USA |
 |
Voyager Therapeutics
VYGR
|
172 M | $ 1.86 | 8.14 % | $ 109 M | USA |
 |
CohBar
CWBR
|
12.4 M | - | -15.44 % | $ 2.2 M | USA |
 |
NeuBase Therapeutics
NBSE
|
4.6 M | - | -1.56 % | $ 12.3 M | USA |
 |
Gossamer Bio
GOSS
|
219 M | $ 9.77 | 3.72 % | $ 2.23 B | USA |
 |
Deciphera Pharmaceuticals
DCPH
|
226 M | - | - | $ 2.18 B | USA |
 |
GeoVax Labs
GOVX
|
24.1 M | $ 0.16 | -5.0 % | $ 153 K | USA |
 |
Arena Pharmaceuticals
ARNA
|
427 M | - | -6.81 % | $ 3.04 B | USA |
 |
Scopus BioPharma
SCPS
|
11.7 M | - | -48.37 % | $ 3.71 M | USA |
 |
Annovis Bio
ANVS
|
29.7 M | $ 0.82 | 23.72 % | $ 16.9 M | USA |
 |
scPharmaceuticals
SCPH
|
36.2 M | - | - | $ 218 M | USA |
 |
Xeris Pharmaceuticals
XERS
|
224 M | $ 15.08 | 15.29 % | $ 2.42 B | USA |
 |
X4 Pharmaceuticals
XFOR
|
87.6 M | $ 3.15 | 2.61 % | $ 133 M | USA |
 |
Entasis Therapeutics Holdings
ETTX
|
52.3 M | - | - | $ 105 M | USA |
 |
Athersys
ATHX
|
79.8 M | - | 3.77 % | $ 22.4 M | USA |
 |
Zai Lab Limited
ZLAB
|
499 M | $ 25.49 | 12.77 % | $ 27.9 B |  China |
 |
Zentalis Pharmaceuticals
ZNTL
|
153 M | $ 1.71 | 2.05 % | $ 123 M | USA |
 |
Zoetis
ZTS
|
6.8 B | $ 79.51 | -3.21 % | $ 35.3 B | USA |
 |
Global Blood Therapeutics
GBT
|
366 M | - | - | $ 4.62 B | USA |
 |
Inozyme Pharma
INZY
|
104 M | - | - | $ 207 M | USA |
 |
Idera Pharmaceuticals
IDRA
|
32.7 M | - | -23.04 % | $ 26.6 M | USA |
 |
NanoString Technologies
NSTG
|
164 M | - | -37.43 % | $ 5.1 M | USA |
 |
Humanigen
HGEN
|
70.8 M | - | -81.12 % | $ 4.28 M | USA |
 |
Sorrento Therapeutics
SRNE
|
232 M | - | -29.58 % | $ 126 M | USA |
 |
Surface Oncology
SURF
|
91.9 M | - | - | $ 59.7 M | USA |
 |
GlaxoSmithKline plc
GSK
|
15.7 B | $ 50.28 | -0.27 % | $ 204 B |  Britain |
 |
Sierra Oncology
SRRA
|
94.6 M | - | -0.05 % | $ 1.34 B |  Canada |
 |
Cocrystal Pharma
COCP
|
9.02 M | $ 1.03 | 2.95 % | $ 11.6 M | USA |
 |
Atea Pharmaceuticals
AVIR
|
181 M | $ 4.27 | 1.18 % | $ 348 M | USA |
 |
Vaccinex
VCNX
|
29 M | - | -61.37 % | $ 654 K | USA |
 |
ImmuCell Corporation
ICCC
|
9.8 M | $ 9.9 | -0.5 % | $ 89.4 M | USA |
 |
Nymox Pharmaceutical Corporation
NYMX
|
11.7 M | - | -19.68 % | $ 18.4 M | Canada |
 |
Akero Therapeutics
AKRO
|
80.2 M | - | - | $ 3.67 B | USA |
 |
Jounce Therapeutics
JNCE
|
134 M | - | - | $ 98.4 M | USA |
 |
Immutep Limited
IMMP
|
16.6 M | $ 3.25 | 20.82 % | $ 4.73 B |  Australia |
 |
Verona Pharma plc
VRNA
|
197 M | - | - | $ 69.7 B | Britain |
 |
Keros Therapeutics
KROS
|
176 M | $ 9.32 | -1.43 % | $ 347 M | USA |
 |
Kazia Therapeutics Limited
KZIA
|
8.82 M | $ 7.19 | 2.71 % | $ 110 M | Australia |
 |
Ligand Pharmaceuticals Incorporated
LGND
|
-41 M | $ 306.2 | 2.41 % | $ 5.92 B | USA |